EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases

被引：0
|
作者：
Jiang, T. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(18)30403-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
129O
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [31] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
    Liam, C. K.
    Ahmad, A. Rozila
    Hsia, T.
    Li, J. Y.
    Le, X.
    Heymach, J.
    Yang, J. C.
    Soo, R.
    Zhang, Y.
    Kim, S.
    Shin, S. W.
    Johne, A.
    Karachaliou, N.
    Bruns, R.
    Ellers-Lenz, B.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119
  • [32] Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1236 - S1236
  • [33] Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs
    Xu, Q.
    Liu, H.
    Xu, Y.
    Zhou, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S93 - S93
  • [34] Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
    Lin, Jessica J.
    Cardarella, Stephanie
    Lydon, Christine A.
    Dahlberg, Suzanne E.
    Jackman, David M.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 556 - 565
  • [35] Effect of intervention timing of CRT combined with third generation EGFR-TKIs in EGFR-mutant NSCLC.
    Deng, Guangchuan
    Li, Zhenxiang
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1732 - S1734
  • [36] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [37] Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
    Ballard, Peter
    Yates, James W. T.
    Yang, Zhenfan
    Kim, Dong-Wan
    Yang, James Chih-Hsin
    Cantarini, Mireille
    Pickup, Kathryn
    Jordan, Angela
    Hickey, Mike
    Grist, Matthew
    Box, Matthew
    Johnstrom, Peter
    Varnas, Katarina
    Malmquist, Jonas
    Thress, Kenneth S.
    Janne, Pasi A.
    Cross, Darren
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5130 - 5140
  • [38] Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
    Xu, Qinghua
    Zhou, Fei
    Liu, Hui
    Jiang, Tao
    Li, Xuefei
    Xu, Yaping
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1383 - 1392
  • [39] Effect of intervention timing of CRT combined non-third generation EGFR-TKIs in EGFR-mutant NSCLC
    Deng, Guangchuan
    Li, Zhenxiang
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1729 - S1730
  • [40] PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
    Bai, Yuchen
    Chen, Xiaoxia
    Hou, Likun
    Qian, Jun
    Jiang, Tao
    Zhou, Caicun
    Ciebiada, Maciej
    CANCER BIOLOGY & MEDICINE, 2018, 15 (04) : 434 - +
12345